-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
All four products submitted by Shijiazhuang Sihua Pharmaceutical Group in the ninth round of national centralized procurement are slated to win bids.
Category:
发布时间：2023-11-07
【概要描述】
On November 6, the ninth round of national centralized bulk procurement of pharmaceuticals—highly anticipated by China’s pharmaceutical industry and the broader public—was opened for bidding in Shanghai. Shijiazhuang Sihua Pharmaceutical Group participated in the bidding for four products across five specifications: azithromycin dry suspension, urapidil hydrochloride injection, tedizolid phosphate for injection, and sodium citicoline injection—and all of these bids were preliminarily awarded.
On November 6, the ninth round of national centralized bulk procurement of pharmaceuticals—highly anticipated by both the domestic pharmaceutical industry and the broader public—was opened for bidding in Shanghai. Shijiazhuang Sihua Pharmaceutical Group participated in the bidding for four products across five specifications: azithromycin dry suspension, urapidil hydrochloride injection, tedizolid phosphate for injection, and sodium citicoline injection—and all of these bids were preliminarily awarded.
According to reports, Shijiazhuang Sihua Pharmaceutical has secured winning bids for a total of three products in this round. Specifically, Azithromycin Dry Suspension (0.1 g) won the bid as the first-ranked supplier and will be supplied to five provinces: Zhejiang, Guangdong, Yunnan, Jilin, and Hebei; Urapidil Hydrochloride Injection (5 ml: 25 mg) (10 ml: 50 mg) also won the bid and will be supplied to four provinces: Zhejiang, Shandong, Anhui, and Yunnan; Teicoplanin Phosphate for Injection (200 mg) secured the win and will be supplied to five provinces: Hebei, Jiangsu, Zhejiang, Guangxi, and Hainan; and Sodium Cytidine Diphosphate Choline Injection (4 ml: 0.5 g) won the bid and will be supplied to three provinces: Yunnan, Zhejiang, and Qinghai.
In recent years, the Group has closely aligned its efforts with the strategic imperative of building a Healthy China. Supported by comprehensive national, provincial, and municipal policies designed to benefit enterprises and foster industrial development, the Group has strived to implement the new development philosophy in a thorough, accurate, and all-encompassing manner. Guided by innovation-driven growth, the Group has focused on emerging fields and cultivated new competitive advantages. By strengthening innovation mechanisms that integrate industry, academia, research, and application, the Group has vigorously advanced the optimization and adjustment of its product portfolio, staying firmly attuned to cutting-edge industry trends and market demands. While concentrating resources on accelerating R&D breakthroughs in innovative drugs, shortage medications, and treatments for rare diseases, the Group has also actively promoted studies on the quality and therapeutic equivalence of generic drugs. Through relentless effort, the Group has achieved significant progress in the consistency evaluation of its generic products. To date, Shijiazhuang No. 4 Pharmaceutical has had a cumulative total of 64 drug varieties comprising 84 dosage forms either successfully pass or be deemed to have passed the consistency evaluation, with 17 varieties encompassing 23 dosage forms having won bids in national centralized procurement. These achievements have laid a solid foundation for further optimizing the product mix, accelerating transformation and upgrading, and driving high-quality development.
A relevant official from the group stated that winning this bid will help further enhance the brand image of the selected products, thereby positively driving the company’s long-term development, boosting regional sales, and strengthening its market influence.
According to reports, this round of centralized procurement covers 42 drug varieties, nearly half of which are injectable formulations. Each variety has at least five participating companies, further enhancing supply diversification and stability. In addition, a notable change in this national procurement is the four-year procurement cycle, which will remain in effect until December 31, 2027—compared with the previous maximum term of three years. This extended timeframe enables companies to better formulate long-term development strategies and avoid market issues such as overcapacity resulting from excessive capacity expansion.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091